• Adaptimmune Ltd., of Oxford, UK, opened a Phase I/IIa, multiple-site, two-cohort, open-label trial in ovarian cancer at Roswell Park Cancer Institute in Buffalo, N.Y., and City of Hope in Duarte, Calif. Researchers will investigate the safety, bioactivity and effectiveness of treating patients with their own T cells after genetically engineering the cells to enhance their antitumor properties.
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Sign up for Perspectives FREE e-mail newsletter